清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

Blinatumoab公司 医学 内科学 微小残留病 肿瘤科 造血干细胞移植 淋巴细胞白血病 化疗 急性淋巴细胞白血病 儿科 移植 白血病
作者
Patrick Andrew Brown,Lingyun Ji,Xinxin Xu,Meenakshi Devidas,Laura E. Hogan,Michael J. Borowitz,Elizabeth A. Raetz,Gerhard Zugmaier,Elad Sharon,Melanie Brooke Bernhardt,Stephanie Alicia Terezakis,Lia Gore,James A. Whitlock,Michael A. Pulsipher,Stephen P. Hunger,Mignon L. Loh
出处
期刊:JAMA [American Medical Association]
卷期号:325 (9): 833-833 被引量:385
标识
DOI:10.1001/jama.2021.0669
摘要

Importance: Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) or late relapse with residual disease after reinduction chemotherapy (intermediate risk). Blinatumomab, a bispecific CD3 to CD19 T cell-engaging antibody construct, is efficacious in relapsed/refractory B-ALL and has a favorable toxicity profile. Objective: To determine whether substituting blinatumomab for intensive chemotherapy in consolidation therapy would improve survival in children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL. Design, Setting, and Participants: This trial was a randomized phase 3 clinical trial conducted by the Children's Oncology Group at 155 hospitals in the US, Canada, Australia, and New Zealand with enrollment from December 2014 to September 2019 and follow-up until September 30, 2020. Eligible patients included those aged 1 to 30 years with B-ALL first relapse, excluding those with Down syndrome, Philadelphia chromosome-positive ALL, prior hematopoietic stem cell transplant, or prior blinatumomab treatment (n = 669). Interventions: All patients received a 4-week reinduction chemotherapy course, followed by randomized assignment to receive 2 cycles of blinatumomab (n = 105) or 2 cycles of multiagent chemotherapy (n = 103), each followed by transplant. Main Outcome and Measures: The primary end point was disease-free survival and the secondary end point was overall survival, both from the time of randomization. The threshold for statistical significance was set at a 1-sided P <.025. Results: Among 208 randomized patients (median age, 9 years; 97 [47%] females), 118 (57%) completed the randomized therapy. Randomization was terminated at the recommendation of the data and safety monitoring committee without meeting stopping rules for efficacy or futility; at that point, 80 of 131 planned events occurred. With 2.9 years of median follow-up, 2-year disease-free survival was 54.4% for the blinatumomab group vs 39.0% for the chemotherapy group (hazard ratio for disease progression or mortality, 0.70 [95% CI, 0.47-1.03]); 1-sided P = .03). Two-year overall survival was 71.3% for the blinatumomab group vs 58.4% for the chemotherapy group (hazard ratio for mortality, 0.62 [95% CI, 0.39-0.98]; 1-sided P = .02). Rates of notable serious adverse events included infection (15%), febrile neutropenia (5%), sepsis (2%), and mucositis (1%) for the blinatumomab group and infection (65%), febrile neutropenia (58%), sepsis (27%), and mucositis (28%) for the chemotherapy group. Conclusions and Relevance: Among children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point. Trial Registration: ClinicalTrials.gov Identifier: NCT02101853.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8秒前
小清完成签到,获得积分10
17秒前
Aaron完成签到,获得积分10
36秒前
41秒前
48秒前
桐桐的应助被葛力采纳,获得10
56秒前
脑洞疼的应助被矢思然采纳,获得10
56秒前
1分钟前
李爱国的应助被搞怪的方盒采纳,获得30
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
烟花的应助被开朗的尔蝶采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
幸福丹蝶完成签到,获得积分10
1分钟前
1分钟前
2分钟前
2分钟前
叫啥好呢完成签到 ,获得积分10
2分钟前
clairewen完成签到,获得积分10
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
3分钟前
矢思然发布了新的文献求助10
3分钟前
3分钟前
葛力发布了新的文献求助10
3分钟前
3分钟前
3分钟前
3分钟前
4分钟前
4分钟前
4分钟前
NN的应助被萧雨墨采纳,获得10
4分钟前
123完成签到 ,获得积分10
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190190
求助须知:如何正确求助?哪些是违规求助? 9577282
关于积分的说明 21852326
捐赠科研通 7788645
什么是DOI,文献DOI怎么找? 3436298
关于科研通互助平台的介绍 2560076
邀请新用户注册赠送积分活动 2482902